These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 33862589

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine.
    Clarkson KA, Talaat KR, Alaimo C, Martin P, Bourgeois AL, Dreyer A, Porter CK, Chakraborty S, Brubaker J, Elwood D, Frölich R, DeNearing B, Weerts HP, Feijoo B, Halpern J, Sack D, Riddle MS, Fonck VG, Kaminski RW.
    EBioMedicine; 2021 Apr; 66():103308. PubMed ID: 33813141
    [Abstract] [Full Text] [Related]

  • 4. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
    Cohen D, Atsmon J, Artaud C, Meron-Sudai S, Gougeon ML, Bialik A, Goren S, Asato V, Ariel-Cohen O, Reizis A, Dorman A, Hoitink CWG, Westdijk J, Ashkenazi S, Sansonetti P, Mulard LA, Phalipon A.
    Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge.
    Kelly M, Janardhanan J, Wagh C, Verma S, Charles RC, Leung DT, Kamruzzaman M, Pansuriya RK, Chowdhury F, Vann WF, Kaminski RW, Khan AI, Bhuiyan TR, Qadri F, Kováč P, Xu P, Ryan ET.
    Vaccine; 2024 Oct 24; 42(24):126263. PubMed ID: 39217775
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
    Passwell JH, Ashkenazi S, Harlev E, Miron D, Ramon R, Farzam N, Lerner-Geva L, Levi Y, Chu C, Shiloach J, Robbins JB, Schneerson R, Israel Shigella Study Group.
    Pediatr Infect Dis J; 2003 Aug 24; 22(8):701-6. PubMed ID: 12913770
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
    Robin G, Keisari Y, Slepon R, Ashkenazi S, Cohen D.
    Vaccine; 1999 Aug 06; 17(23-24):3109-15. PubMed ID: 10462247
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects.
    Chakraborty S, Harro C, DeNearing B, Bream J, Bauers N, Dally L, Flores J, Van de Verg L, Sack DA, Walker R.
    Clin Vaccine Immunol; 2016 Apr 06; 23(4):315-25. PubMed ID: 26865592
    [Abstract] [Full Text] [Related]

  • 12. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children.
    Passwell JH, Ashkenazi S, Banet-Levi Y, Ramon-Saraf R, Farzam N, Lerner-Geva L, Even-Nir H, Yerushalmi B, Chu C, Shiloach J, Robbins JB, Schneerson R, Israeli Shigella Study Group.
    Vaccine; 2010 Mar 02; 28(10):2231-2235. PubMed ID: 20056180
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.
    Shim DH, Chang SY, Park SM, Jang H, Carbis R, Czerkinsky C, Uematsu S, Akira S, Kweon MN.
    Vaccine; 2007 Jun 15; 25(25):4828-36. PubMed ID: 17507120
    [Abstract] [Full Text] [Related]

  • 14. Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study.
    Shimanovich AA, Buskirk AD, Heine SJ, Blackwelder WC, Wahid R, Kotloff KL, Pasetti MF.
    Clin Vaccine Immunol; 2017 Feb 15; 24(2):. PubMed ID: 27927680
    [Abstract] [Full Text] [Related]

  • 15. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.
    Cohen D, Ashkenazi S, Green MS, Gdalevich M, Robin G, Slepon R, Yavzori M, Orr N, Block C, Ashkenazi I, Shemer J, Taylor DN, Hale TL, Sadoff JC, Pavliakova D, Schneerson R, Robbins JB.
    Lancet; 1997 Jan 18; 349(9046):155-9. PubMed ID: 9111538
    [Abstract] [Full Text] [Related]

  • 16. Safety and Immunogenicity of a 4-Component Generalized Modules for Membrane Antigens Shigella Vaccine in Healthy European Adults: Randomized, Phase 1/2 Study.
    Leroux-Roels I, Maes C, Mancini F, Jacobs B, Sarakinou E, Alhatemi A, Joye J, Grappi S, Cilio GL, Serry-Bangura A, Vitali CG, Ferruzzi P, Marchetti E, Necchi F, Rappuoli R, De Ryck I, Auerbach J, Colucci AM, Rossi O, Conti V, Scorza FB, Arora AK, Micoli F, Podda A, Nakakana UN, Shigella Project Team.
    J Infect Dis; 2024 Oct 16; 230(4):e971-e984. PubMed ID: 38853614
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2.
    Kotloff KL, Losonsky GA, Nataro JP, Wasserman SS, Hale TL, Taylor DN, Newland JW, Sadoff JC, Formal SB, Levine MM.
    Vaccine; 1995 Apr 16; 13(5):495-502. PubMed ID: 7639017
    [Abstract] [Full Text] [Related]

  • 18. Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers.
    Tribble D, Kaminski R, Cantrell J, Nelson M, Porter C, Baqar S, Williams C, Arora R, Saunders J, Ananthakrishnan M, Sanders J, Zaucha G, Turbyfill R, Oaks E.
    Vaccine; 2010 Aug 23; 28(37):6076-85. PubMed ID: 20619378
    [Abstract] [Full Text] [Related]

  • 19. Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine.
    Riddle MS, Kaminski RW, Williams C, Porter C, Baqar S, Kordis A, Gilliland T, Lapa J, Coughlin M, Soltis C, Jones E, Saunders J, Keiser PB, Ranallo RT, Gormley R, Nelson M, Turbyfill KR, Tribble D, Oaks EV.
    Vaccine; 2011 Sep 16; 29(40):7009-19. PubMed ID: 21787825
    [Abstract] [Full Text] [Related]

  • 20. Highly homogenous tri-acylated S-LPS acts as a novel clinically applicable vaccine against Shigella flexneri 2a infection.
    Ledov VA, Golovina ME, Markina AA, Knirel YA, L'vov VL, Kovalchuk AL, Aparin PG.
    Vaccine; 2019 Feb 14; 37(8):1062-1072. PubMed ID: 30670300
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.